ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best Robinhood stocks on this list.

TheFly reported on March 11 that BTIG gave IBRX a Buy rating and assigned a $13 price target. The firm pointed to the stock’s strong performance in 2026, supported by rapid year-over-year growth in U.S. ANKTIVA sales, conditional marketing authorization in the European Union, and NSCLC approval in Saudi Arabia. BTIG also said additional upside could come from continued commercial progress for ANKTIVA and potential expansion of its approved uses.

Additionally, on March 13, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) announced it had completed its NK2022 and NK2023 manufacturing engineering programs, advancing a leukapheresis-to-production process for its autologous memory cytokine-enhanced natural killer cell therapy platform.

The company also said a Phase 1 study combining M-ceNK with ANKTIVA in relapsed or refractory tumor patients was completed and showed the treatment was well-tolerated after infusion.

Together, the programs enrolled 74 participants, including healthy donors and cancer patients, and produced key process development and robotic automation data for future clinical use. IBRX reported that 64 participants completed apheresis without serious procedure-related adverse events. In addition, 10 cancer patients received 23 doses, with no serious adverse events reported during treatment.

ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotech company developing and commercializing immunotherapies, led by ANKTIVA, to treat cancer and infectious diseases by activating the body’s immune system.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.